Weighing the Options: Which PrEP (Pre-exposure Prophylaxis) Modality Attributes Influence Choice for Young Gay and Bisexual Men in the United States?
HIV
Long-Acting PrEP
Next Generation PrEP
PrEP
Product Preference
YMSM
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
10 Aug 2024
10 Aug 2024
Historique:
accepted:
15
05
2024
medline:
10
8
2024
pubmed:
10
8
2024
entrez:
10
8
2024
Statut:
aheadofprint
Résumé
Pre-exposure prophylaxis (PrEP) is effective in preventing HIV transmission, but uptake and adherence among young men who have sex with men (YMSM) remains suboptimal. New PrEP formulations may enhance PrEP use, but little is known about their acceptability. We enrolled 39 cis- and transgender YMSM (age 18-34) from Boston, MA; Jackson, MS; Birmingham, AL; and New Orleans, LA, who participated in video-based focus groups (n = 30) or in-depth interviews (n = 9) to examine how new PrEP products (e.g., injections, monthly pills, implants) are perceived and might be improved for YMSM. Focus groups were transcribed, coded, and analyzed using grounded theory and content analysis. Nearly half (46%) of participants were Black; 11% identified as Hispanic. Seventy-nine percent were PrEP experienced. Product preference was driven by the desire for flexible, safe, effective, and affordable PrEP options. A majority of participants preferred subcutaneous injections every 6 months or monthly pills dispersed in 3 or 4 doses. Subcutaneous injections and batched monthly pills were favored by those with demanding schedules and those who desired fewer provider visits; monthly pills were more appealing for those who feared needles. Despite broad preferences for longer-acting products for convenience, participants raised concerns regarding side effects and waning protection after missed doses. Participants felt that more education about safety and efficacy profiles of new products could influence their attitudes. These findings suggest that it is important to prioritize YMSM's dynamic lifestyles during product development, and that product safety and efficacy information should be accessible in youth-friendly language.
Identifiants
pubmed: 39126557
doi: 10.1007/s10461-024-04384-1
pii: 10.1007/s10461-024-04384-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Merck
ID : Merck
Organisme : Division of Intramural Research, National Institute of Allergy and Infectious Diseases
ID : P30AI042853
Informations de copyright
© 2024. Merck & Co., Inc., Rahway, NJ, USA and its affiliates & Jonathan HillRorie, Katie Biello, Meg Quint, Bernadette Johnson, Latesha Elopre, Kendra Johnson, Rebecca Lillis, Kaylee Burgan, Douglas Krakower, Kenneth H. Mayer.
Références
Pitasi MA, Beer L, Cha S, et al. Vital signs: HIV infection, diagnosis, treatment, and Prevention among Gay, Bisexual, and other men who have sex with men — United States, 2010–2019. MMWR Morb Mortal Wkly Rep. 2021;70:1669–75. https://doi.org/10.15585/mmwr.mm7048e1
doi: 10.15585/mmwr.mm7048e1
pubmed: 34855721
pmcid: 8641567
Centers for Disease Control and Prevention, Surveillance Report HIV. 2021; vol. 34. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html . Published May 2023. Accessed [Sep 2023].
U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents [press release]. 2018.
Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125. https://doi.org/10.1126/scitranslmed.3004006
doi: 10.1126/scitranslmed.3004006
pubmed: 22972843
pmcid: 3721979
Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.
doi: 10.1016/S1473-3099(14)70847-3
pubmed: 25065857
pmcid: 6107918
McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.
doi: 10.1016/S0140-6736(15)00056-2
pubmed: 26364263
pmcid: 4700047
Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, et al. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States. JAMA Pediatr. 2017;171(11):1063–71.
doi: 10.1001/jamapediatrics.2017.2007
pubmed: 28873128
pmcid: 5710370
Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, et al. An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. J Acquir Immune Defic Syndr. 2017;74(1):21–9.
doi: 10.1097/QAI.0000000000001179
pubmed: 27632233
pmcid: 5140725
Mullins TLK, Zimet G, Lally M, Xu J, Thornton S, Kahn JA. HIV Care Providers’ intentions to prescribe and actual prescription of Pre-exposure Prophylaxis to At-Risk adolescents and adults. AIDS Patient Care STDS. 2017;31(12):504–16.
doi: 10.1089/apc.2017.0147
pubmed: 29211514
pmcid: 5724583
Arrington-Sanders R, Morgan A, Oidtman J, Qian I, Celentano D, Beyrer C. A Medical Care missed opportunity: Preexposure Prophylaxis and Young Black men who have sex with men. J Adolesc Health. 2016;59(6):725–8.
doi: 10.1016/j.jadohealth.2016.08.006
pubmed: 27720357
Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, Cabello R, Chariyalertsak S, Dunne EF, Frank I, Gallardo-Cartagena JA. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595–608.
doi: 10.1056/NEJMoa2101016
pubmed: 34379922
pmcid: 8448593
Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, Kayange N, Makhema J, Mandima P, Mathew C, Spooner E. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779–89.
doi: 10.1016/S0140-6736(22)00538-4
pubmed: 35378077
pmcid: 9077443
Garg S, Goldman D, Krumme M, Rohan LC, Smoot S, Friend DR. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Antiviral Res. 2010;88:S19–29.
doi: 10.1016/j.antiviral.2010.09.010
pubmed: 21109064
McGowan I. Microbicides for HIV prevention: reality or hope? Curr Opin Infect Dis. 2010;23(1):26–31.
doi: 10.1097/QCO.0b013e328334fe70
pubmed: 19935418
Rosenberg ZF, Devlin B. Future strategies in microbicide development. Best Pract Res Clin Obstet Gynecol. 2012;26(4):503–13.
doi: 10.1016/j.bpobgyn.2012.02.001
Zapata JP, Petroll A, de St Aubin E, Quinn K. Perspectives on Social Support and Stigma in PrEP-related care among gay and bisexual men: a qualitative investigation. J Homosex. 2022;69(2):254–76. Epub 2020 Sep 22. PMID: 32960750.
doi: 10.1080/00918369.2020.1819709
pubmed: 32960750
Biello KB, Hosek S, Drucker MT, Belzer M, Mimiaga MJ, Marrow E, et al. Preferences for Injectable PrEP among Young U.S. Cisgender men and Transgender women and men who have sex with men. Arch Sex Behav. 2018;47(7):2101–7.
doi: 10.1007/s10508-017-1049-7
pubmed: 28929260
Javanbakht M, Stahlman S, Pickett J, LeBlanc M-A, Gorbach PM. Prevalence and types of rectal douches used for anal intercourse: results from an international survey. BMC Infect Dis. 2014;14(1):95.
doi: 10.1186/1471-2334-14-95
pubmed: 24555695
pmcid: 4015843
Biello KB, Valente PK, Lin WY, Lodge Ii W, Drab R, Hightow-Weidman L, da Silva DT, Mayer K, Bauermeister JA. PrEParing for NextGen: cognitive interviews to Improve Next Generation PrEP modality descriptions for Young men who have sex with men. AIDS Behav. 2022;26(6):1956–65. Epub 2021 Dec 3. PMID: 34860304; PMCID: PMC9050851.
doi: 10.1007/s10461-021-03545-w
pubmed: 34860304
PrEPWatch. Products. https://www.prepwatch.org/products/ Accessed [March 2024].
Valente PK, Mimiaga MJ, Chan PA, Biello KB. Health Service- and provider-level factors influencing Engagement in HIV Pre-exposure Prophylaxis Care among Male Sex workers. AIDS Patient Care STDS. 2021;35(8):279–87. https://doi.org/10.1089/apc.2021.0084 . PMID: 34375139; PMCID: PMC8380801.
doi: 10.1089/apc.2021.0084
pubmed: 34375139
pmcid: 8380801
Holloway I, Dougherty R, Gildner J, Beougher SC, Pulsipher C, Montoya JA et al. PrEP Uptake, Adherence, and Discontinuation among California YMSM Using Geosocial Networking Applications. J Acquir Immune Defic Syndr. 1999. 2017. January.
Whitfield THF, John SA, Rendina HJ, Grov C, Parsons JT. Why I quit Pre-exposure Prophylaxis (PrEP)? A mixed-method study exploring reasons for PrEP discontinuation and potential re-initiation among Gay and Bisexual men. AIDS Behav. 2018. November;22(11):3566–75. https://doi.org/10.1007/s10461-018-2045-1
Spinelli MA, Scott HM, Vittinghoff E, Liu AY, Gonzalez R, Morehead-Gee A et al. Missed Visits Associated With Future Preexposure Prophylaxis (PrEP) Discontinuation Among PrEP Users in a Municipal Primary Care Health Network. Open Forum Infect Dis [Internet]. 2019. April 1 [cited 2019 Aug 22];6(4). https://academic.oup.com/ofid/article/doi/ https://doi.org/10.1093/ofid/ofz101/5365426
Asiago-Reddy EA, McPeak J, Scarpa R, Braksmajer A, Ruszkowski N, McMahon J, London AS. Perceived access to PrEP as a critical step in engagement: a qualitative analysis and discrete choice experiment among young men who have sex with men. PLoS ONE. 2022;17(1):e0258530. https://doi.org/10.1371/journal.pone.0258530 . PMID: 35081116; PMCID: PMC8791519.
doi: 10.1371/journal.pone.0258530
pubmed: 35081116
pmcid: 8791519
Bonacci RA, Van Handel M, Huggins R, Inusah S, Smith DK. Estimated Uncovered Costs For HIV Preexposure Prophylaxis In The US, 2018. Health Aff (Millwood). 2023;42(4):546–555. https://doi.org/10.1377/hlthaff.2022.00523 . PMID: 37011310; PMCID: PMC10206677.
D’Angelo AB, Lopez-Rios J, Flynn AWP, Holloway IW, Pantalone DW, Grov C. Insurance- and medical provider-related barriers and facilitators to staying on PrEP: results from a qualitative study. Transl Behav Med. 2021;11(2):573–81. https://doi.org/10.1093/tbm/ibz191 . PMID: 32065637; PMCID: PMC7963286.
doi: 10.1093/tbm/ibz191
pubmed: 32065637
Nieto O, Brooks RA, Landrian A, Cabral A, Fehrenbacher AE. PrEP discontinuation among Latino/a and Black MSM and transgender women: a need for PrEP support services. PLoS ONE. 2020;15(11):e0241340. https://doi.org/10.1371/journal.pone.0241340 . PMID: 33151997; PMCID: PMC7644013.
doi: 10.1371/journal.pone.0241340
pubmed: 33151997
pmcid: 7644013
Huebner DM, Mustanski B. Navigating the Long Road Forward for Maximizing PrEP Impact Among Adolescent Men Who Have Sex with Men. Arch Sex Behav. 2020;49(1):211–216. Doi: 10.1007/s10508-019-1454-1. Epub 2019 Oct 30. PMID: 31667642; PMCID: PMC7665846.
Dubov A, Ogunbajo A, Altice FL, Fraenkel L. Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment. AIDS Care. 2019;31(5):545–53. https://doi.org/10.1080/09540121.2018.1557590 . Epub 2018 Dec 15. PMID: 30554519; PMCID: PMC6408226.
doi: 10.1080/09540121.2018.1557590
pubmed: 30554519
Annequin M, Villes V, Delabre RM, Alain T, Morel S, Michels D, Schmidt AJ, Velter A, Rojas Castro D. Are PrEP services in France reaching all those exposed to HIV who want to take PrEP? MSM respondents who are eligible but not using PrEP (EMIS 2017). AIDS Care. 2020;32(sup2):47–56. Epub 2020 Mar 19. PMID: 32189518.
doi: 10.1080/09540121.2020.1739219
pubmed: 32189518
Dunn Navarra AM, Whittemore R, Bakken S, Rosenberg MJ, Gormley M, Bethea J, Gwadz M, Cleland C, Liang E, D’Eramo Melkus G. Adherence self-management and the influence of contextual factors among emerging adults with Human Immunodeficiency Virus. Nurs Res 2020 May/Jun;69(3):197–209. https://doi.org/10.1097/NNR.0000000000000422 . PMID: 31972851; PMCID: PMC7286659.
Ying X, Kahn P, Mathis WS. Pharmacy deserts: More than where pharmacies are. J Am Pharm Assoc (2003). 2022 Nov-Dec;62(6):1875–1879. https://doi.org/10.1016/j.japh.2022.06.016 . Epub 2022 Jul 5. PMID: 35953379.
Wisseh C, Hildreth K, Marshall J, Tanner A, Bazargan M, Robinson P. Social determinants of Pharmacy deserts in Los Angeles County. J Racial Ethn Health Disparities. 2021;8(6):1424–34. https://doi.org/10.1007/s40615-020-00904-6 . Epub 2020 Oct 27. PMID: 33111234; PMCID: PMC8076330.
doi: 10.1007/s40615-020-00904-6
pubmed: 33111234
Rader B, Astley CM, Sewalk K, Delamater PL, Cordiano K, Wronski L, Rivera JM, Hallberg K, Pera MF, Cantor J, Whaley CM, Bravata DM, Lee L, Patel A, Brownstein JS. Spatial modeling of vaccine deserts as barriers to controlling SARS-CoV-2. Commun Med (Lond). 2022;2(1):141. https://doi.org/10.1038/s43856-022-00183-8 . PMID: 36357587; PMCID: PMC9649755.
doi: 10.1038/s43856-022-00183-8
pubmed: 36357587
Radford CE, James KE, Clapp M, Bryant AS, Goldfarb IT. Availability Versus Accessibility: Identifying COVID-19 Testing Deserts Across Massachusetts. Health Aff (Millwood). 2023;42(5):712–720. https://doi.org/10.1377/hlthaff.2022.00683 . PMID: 37126759.
Liu A, Coleman K, Walker N, Vittinghoff E, Turner C, Vinson J et al. Assessing the PrEP Continuum in the San Francisco Bay Area: The Quickie Mobile Survey. Conference on Retroviruses and Opportunistic Infections (CROI); 2019; Seattle, WA.
Morgan E, Ryan DT, Newcomb ME, Mustanski B. High rate of Discontinuation May Diminish PrEP Coverage among Young men who have sex with men. AIDS Behav. 2018. November;22(11):3645–8.
Hojilla JC, Vlahov D, Crouch P-C, Dawson-Rose C, Freeborn K, Carrico A. HIV Pre-exposure Prophylaxis (PrEP) Uptake and Retention Among Men Who Have Sex with Men in a Community-Based Sexual Health Clinic. AIDS Behav. 2018. April 1;22(4):1096–9. https://doi.org/10.1007/s10461-017-2009-x